Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (ADCT) is a commercial-stage biopharmaceutical leader pioneering antibody drug conjugates (ADCs) for advanced oncology treatments. This page serves as the definitive source for all company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases and news articles detailing ADCT's progress in developing targeted therapies for hematologic malignancies and solid tumors. Our collection includes updates on product commercialization, clinical study results, and research collaborations, providing critical insights into the company's scientific and operational trajectory.
Key content categories cover quarterly financial results, FDA/EMA regulatory filings, and advancements in ADC technology. Bookmark this page to stay informed about ADCT's innovations in precision oncology and its growing impact on cancer treatment paradigms.
ADC Therapeutics reported financial results for the second quarter of 2022, highlighting net sales for ZYNLONTA® at $17.3 million, up from $3.8 million year-over-year. The company established a license agreement with Sobi® to enhance global access to ZYNLONTA, extending its cash runway to early 2025. Notable advancements include the initiation of multiple clinical trials, including LOTIS-9 and LOTIS-7. Net loss for the quarter was $64.4 million, showing an improvement compared to the previous year. ADC's focus on increasing product awareness is expected to support ongoing growth.
ADC Therapeutics (NYSE: ADCT) announced a conference call and webcast scheduled for August 9, 2022, at 8:30 a.m. ET to disclose its Q2 2022 financial results and share business updates. The call will provide investors with insights into the company’s performance and operations. ADC Therapeutics specializes in targeted antibody drug conjugates for cancer treatment, including the FDA-approved ZYNLONTA for diffuse large B-cell lymphoma, and ongoing developments in its ADC pipeline.
ADC Therapeutics announced the initiation of a Phase 1b clinical trial for ADCT-601 (mipasetamab uzoptirine), targeting AXL in patients with advanced solid tumors. The trial aims to assess ADCT-601's safety as a standalone and in combination with gemcitabine, particularly in sarcoma, a tumor resistant to current treatments. ADCT-601 has shown a manageable tolerability profile and promising preclinical synergy with gemcitabine. This advancement continues ADC Therapeutics' focus on improving cancer treatment through targeted antibody-drug conjugates.
ADC Therapeutics has initiated the LOTIS-9 Phase 2 clinical trial, targeting unfit and frail patients with previously untreated DLBCL. This trial aims to evaluate the efficacy and tolerability of ZYNLONTA (loncastuximab tesirine-lpyl) combined with rituximab in approximately 80 patients aged 80 and older. The trial follows promising results from the LOTIS-5 Phase 3 trial, addressing a significant medical need in a typically underserved population. The study may pave the way for new treatment options for these patients.
Overland ADCT BioPharma has initiated its Phase 3 LOTIS-5 trial in China, dosing the first patient with ZYNLONTA® combined with rituximab for DLBCL. This follows ZYNLONTA's accelerated FDA approval as a single-agent therapy for relapsed DLBCL. The trial aims to support a supplemental BLA in the U.S. and China for transplant-ineligible patients. This significant milestone reflects the commitment to advancing treatment options for patients with difficult-to-treat DLBCL in China.
ADC Therapeutics announced the appointment of Jean-Pierre Bizzari, MD, to its Board of Directors, enhancing its oncology expertise. Ameet Mallik, CEO since May 2022, also joins the Board. Dr. Bizzari brings over 35 years of experience, having previously overseen critical oncology product developments at Celgene and Sanofi-Aventis. His extensive background is expected to bolster ADC Therapeutics' pipeline of antibody drug conjugates for treating hematological cancers and solid tumors, especially after the FDA approval of ZYNLONTA®.
ADC Therapeutics has announced the dosing of the first patient in the LOTIS-7 Phase 1b clinical trial, examining the efficacy of ZYNLONTA in combination with polatuzumab vedotin for treating relapsed or refractory B-cell non-Hodgkin lymphoma.
The trial aims to evaluate ZYNLONTA's safety and activity against various types of B-cell lymphomas, with a focus on achieving better responses in patients. This trial follows promising preclinical studies that indicated potential synergies with other therapies.
ADC Therapeutics has appointed David Gilman as the new Chief Business & Strategy Officer, effective July 1st. With over 25 years of experience in the life sciences sector, Gilman will be responsible for global business development and portfolio strategy, reporting directly to CEO Ameet Mallik. His previous roles include Global Head of Portfolio Strategy at Novartis and significant contributions at ClearView Healthcare Partners.
This strategic appointment aims to strengthen ADC Therapeutics' leadership at a critical time for the company.
ADC Therapeutics announced encouraging results from its Phase 2 trial of camidanlumab tesirine (Cami) for relapsed/refractory Hodgkin lymphoma. The trial showed an overall response rate of 70.1% and a complete response rate of 33.3%. Patients experienced a median duration of response of 13.7 months, with a safety profile consistent with prior findings. The company is preparing to discuss a potential Biologics License Application submission with the FDA following these promising results presented at the European Hematology Association Hybrid Congress.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
